

117TH CONGRESS
2D SESSION

H. RES. 1284

Of inquiry directing the Secretary of Health and Human Services to provide certain documentation to the House of Representatives relating to the negotiation of prices for prescription drugs under the Medicare prescription drug program.

IN THE HOUSE OF REPRESENTATIVES

JULY 26, 2022

Mrs. RODGERS of Washington submitted the following resolution; which was referred to the Committee on Energy and Commerce

RESOLUTION

Of inquiry directing the Secretary of Health and Human Services to provide certain documentation to the House of Representatives relating to the negotiation of prices for prescription drugs under the Medicare prescription drug program.

1 *Resolved*, That the Secretary of Health and Human
2 Services (referred to herein as the “Secretary”) is directed
3 to furnish to the House of Representatives, not later than
4 14 days after adoption of this resolution, copies of any
5 document, record, audio recording, memorandum, call log,
6 correspondence (electronic or otherwise), or other commu-
7 nication in the Secretary’s possession, or any portion of

1 any document, record, audio recording, memorandum, call
2 log, correspondence (electronic or otherwise), or other
3 communication in the Secretary's possession, that refers
4 or relates to any of the following:

5 (1) Communications by staff of the White
6 House with any group or expert that is not staff of
7 the White House regarding the implications of im-
8 posing a 95 percent excise tax on drug manufactur-
9 ers that fail to comply with price setting negotiations
10 with the Secretary under the Medicare prescription
11 drug program under part D of title XVIII of the So-
12 cial Security Act and the potential loss of the devel-
13 opment of future drugs and cures.

14 (2) Internal communications among staff of the
15 White House regarding the implications described in
16 paragraph (1) and the potential loss of development
17 described in such paragraph.

18 (3) Communications by staff of the White
19 House with any group or expert that is not staff of
20 the White House regarding the implications of estab-
21 lishing inflation penalties under the Medicare pre-
22 scription drug program under such part D on launch
23 prices for future prescription drugs.

1 (4) Internal communications among staff of the
2 White House regarding the implications described in
3 paragraph (3).

○